JPRN-jRCT2031210117进行中（未招募）3 期
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer disease (EVOKE plus)(NN6535-4725) - EVOKE plus
Ohsugi Toshiaki0 个研究点目标入组 139 人开始时间: 2021年5月27日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 139
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 55age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •1. MCI or mild dementia of the Alzheimer type according to the NIA-AA 2018 criteria.
- •2. CDR global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home & hobbies, community affairs) Or CDR global score of 1.0
- •3. RBANS delayed memory index score of <=85
- •4. MMSE>=22
- •5. Amyloid positivity established with either amyloid PET or CSF Abeta1-42.
- •6. If receiving an approved Alzheimer disease treatment (such as acetylcholinesterase inhibitors or memantine) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary.
排除标准
- •1. Brain MRI (or CT) scan suggestive of clinically significant structural CNS disease confirmed by central read (e.g. cerebral large-vessel disease [large vessel (cortical) infarcts >10 mm in diameter], prior macro-haemorrhage [>1 cm3], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus).
- •2. Brain MRI (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read.
- •3. Evidence of a relevant neurological disorder other than MCI or mild dementia of the Alzheimer type at screening, including but not limited to Parkinson disease, Lewy body disease, frontotemporal dementia of any type, Huntington disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, HIV, learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits.
- •4. Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator judgement.
研究者
相似试验
进行中（未招募）
1 期
A research study looking at the effect of semaglutide on the immune system and other biological processes in people with Alzheimer’s diseaseEUCTR2022-003384-24-DKovo Nordisk A/S24
进行中（未招募）
1 期
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)CTIS2023-506919-18-00ovo Nordisk A/S1,855
进行中（未招募）
1 期
A research study investigating semaglutide in people with early Alzheimer’s disease (EVOKE plus)Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s typeMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-004864-25-ATovo Nordisk A/S1,840
进行中（未招募）
1 期
A research study investigating semaglutide in people with early Alzheimer’s disease (EVOKE)Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s typeMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2020-004848-29-CZovo Nordisk A/S1,840
进行中（未招募）
1 期
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s typeMedDRA version: 20.0Level: LLTClassification code: 10001896Term: Alzheimer's disease Class: 10029205CTIS2023-506918-45-00ovo Nordisk A/S1,953